RE:RE:Pre-clinical Trillium Technologies was acquired for US$2.3 BAs posted beforehand, Pfizer's US$2.3 Billion of the pre-clinical Trillium Therapeutics is another good example of the type of premiums Big Pharma are having to pay for upstream biological drug assets that still remain in the pre-clinical stage.
ONCY on the otherhand is a late stage biological drug development company in a Phase 3 ready state in multiple cancer indications, including pancreatic, breast, anal, and colorectal cancer.
Furthermore, ONCYs pelareorep is a candidate for synergistic combinations with immune checkpoint inhibitors, CAR-T therapies, bispecifics, PARP, and CDK4,6 inhibitors, for example.
Consequently, ONCY's acquisition valuation is far greater than the Anson Fund Management trolls are concertedly trying to suggest in their public smear campaign, that is currently happening on multiple ONCY message boards.
https://www.barchart.com/stocks/quotes/TRIL